Bryn Mawr Capital Management LLC Has $961,000 Holdings in Novartis AG (NYSE:NVS)

Bryn Mawr Capital Management LLC trimmed its position in Novartis AG (NYSE:NVS - Free Report) by 22.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,873 shares of the company's stock after selling 2,911 shares during the period. Bryn Mawr Capital Management LLC's holdings in Novartis were worth $961,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in NVS. Foundations Investment Advisors LLC boosted its position in shares of Novartis by 26.9% during the 4th quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company's stock valued at $8,668,000 after purchasing an additional 18,894 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Novartis by 115.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company's stock valued at $26,797,000 after purchasing an additional 124,111 shares during the last quarter. CWA Asset Management Group LLC boosted its holdings in Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company's stock worth $3,001,000 after buying an additional 5,164 shares in the last quarter. Quantbot Technologies LP grew its position in Novartis by 135.5% in the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company's stock worth $4,598,000 after buying an additional 22,998 shares during the last quarter. Finally, Chicago Partners Investment Group LLC bought a new position in shares of Novartis in the fourth quarter valued at $239,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NVS. StockNews.com raised Novartis from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 8th. HSBC downgraded shares of Novartis from a "hold" rating to a "reduce" rating in a research report on Wednesday, December 4th. BMO Capital Markets raised their price objective on shares of Novartis from $118.00 to $120.00 and gave the stock a "market perform" rating in a research note on Wednesday, October 30th. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a "hold" rating to a "buy" rating in a research report on Tuesday, February 4th. Finally, Erste Group Bank reaffirmed a "hold" rating on shares of Novartis in a research report on Tuesday, November 19th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $123.38.

Novartis Stock Up 2.0 %

Shares of NYSE:NVS traded up $2.11 during trading on Friday, reaching $109.42. 2,274,792 shares of the company traded hands, compared to its average volume of 1,952,208. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The firm has a market cap of $223.65 billion, a P/E ratio of 18.61, a price-to-earnings-growth ratio of 1.70 and a beta of 0.58. The firm has a fifty day simple moving average of $101.24 and a 200 day simple moving average of $108.15.

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Analysts anticipate that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.